Aptevo Therapeutics Inc.
APVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671584
No open-market purchases or sales by Aptevo Therapeutics Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $224.3K in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Aptevo Therapeutics Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 7 | 12 | +5 |
| Shares | 15.0K | 494.0K | +479.0K (+3,185.6%) |
| Value | $45.9K | $717.1K | +$671.3K (+1,463.9%) |
New holders (6)
Institutions that held Aptevo Therapeutics Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Point72 Asset Management, L.P. | 299,944 | $434.9K | 0.00% |
| DRW Securities, LLC | 131,480 | $190.6K | 0.01% |
| Virtu Financial LLC | 38,282 | $56.0K | 0.00% |
| Colony Group, LLC | 10,000 | $14.5K | 0.00% |
| UBS Group AG | 5,673 | $8.23K | 0.00% |
| Citigroup Inc | 74 | $107 | 0.00% |
Sold out (1)
Institutions that held Aptevo Therapeutics Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Birchview Capital, LP | 10,000 | $30.5K |